Imugene Limited
IUGNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $113 | $435 | $560 | $1,102 |
| - Cash | $22 | $93 | $153 | $100 |
| + Debt | $11 | $2 | $1 | $1 |
| Enterprise Value | $102 | $343 | $407 | $1,003 |
| Revenue | $4 | $5 | $12 | $13 |
| % Growth | -11.5% | -57.8% | -9.2% | – |
| Gross Profit | $4 | $5 | $10 | $11 |
| % Margin | 100% | 100% | 81.3% | 81.4% |
| EBITDA | -$67 | -$148 | -$47 | -$35 |
| % Margin | -1,533.5% | -2,977.4% | -402.7% | -272.1% |
| Net Income | -$69 | -$150 | -$38 | -$38 |
| % Margin | -1,569.8% | -3,011.7% | -321.9% | -292% |
| EPS Diluted | -0.32 | -0.72 | -0.21 | -0.23 |
| % Growth | 55.6% | -242.9% | 8.7% | – |
| Operating Cash Flow | -$76 | -$102 | -$30 | -$31 |
| Capital Expenditures | -$14 | -$7 | $0 | -$0 |
| Free Cash Flow | -$90 | -$109 | -$30 | -$31 |